Third Harmonic Bio Inc - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים THRD

Third Harmonic Bio (THRD) faces binary risks due to the concentration of resources on a single drug. The company is developing oral treatments for skin inflammation, replacing injections with the convenience of tablets. Investments in the KIT inhibitor system create a closed scientific loop. The TTM annual revenue growth rate reflects the business dynamics, where the 0.00 mark indicates the level of the current trend.
Third Harmonic Bio, Inc (THRD) - פילוחי מדדים ודוחות פיננסיים

To minimize fundamental risks, investors should select assets with sustainable revenue dynamics, which this indicator measures via a rolling twelve-month comparison of current earnings against the same period last year. For Third Harmonic Bio (THRD), the year-over-year sales trajectory (TTM) will serve as a critical marker for the commercialization of selective inhibitors following the completion of clinical trials and the market launch of the drugs.